Pain Management with Opioid Analgesics

被引:2
作者
Stanos, Steven P. [1 ]
Fishbain, David A. [1 ]
Fishman, Scott M. [1 ]
机构
[1] Rehabil Inst Chicago, Ctr Pain Management, Chicago, IL 60611 USA
关键词
Chronic Pain; Pain Management; Opioid Analgesics; Drug Abuse; CHRONIC NONMALIGNANT PAIN; CHRONIC NONCANCER PAIN; OXYMORPHONE EXTENDED-RELEASE; FENTANYL BUCCAL TABLET; QUALITY-OF-LIFE; PHARMACOKINETIC DRUG-INTERACTIONS; PRIMARY-CARE PHYSICIAN; STATE MEDICAL BOARDS; LONG-TERM USE; NEUROPATHIC PAIN;
D O I
10.1097/PHM.0b013e318198dcf7
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
The "opioid pendulum" swings between providing adequate pain relief and preventing addiction, without solving either problem sufficiently. Policies to address prescription drug abuse in the United States sometimes appear to contradict a practice environment in which chronic pain can be adequately treated. Pharmacovigilance when prescribing controlled substances for chronic pain requires physicians to first make a risk/benefit analysis and then to reassess during ongoing treatment. It is important that physicians document this analysis with transparency so regulators can see that risk is being assessed and managed. Physicians must balance the benefits and risks of COAT so that they can continue to treat pain effectively and improve functional outcomes, while at the same time avoid indiscriminate prescribing. Physicians have an obligation to be thorough, thoughtful, logically consistent, and careful-but there is no realistic expectation that they will always be "right." Advances in the science and art of medicine emphasize rational patient assessment and selection for treatment, the benefits and limitations of pharmacologic and nonpharmacologic management, and careful monitoring. Even small changes to clinical practice can promote safe controlled substances prescribing, and will likely improve the overall standard of care. Copyright © 2009 by Lippincott Williams & Wilkins.
引用
收藏
页码:S69 / S99
页数:31
相关论文
共 248 条
  • [1] Endocrine consequences of long-term intrathecal administration of opioids
    Abs, R
    Verhelst, J
    Maeyaert, J
    Van Buyten, JP
    Opsomer, F
    Adriaensen, H
    Verlooy, J
    Van Havenbergh, T
    Smet, M
    Van Acker, K
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (06) : 2215 - 2222
  • [2] Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways
    Adams, M
    Pieniaszek, HJ
    Gammaitoni, AR
    Ahdieh, H
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (03) : 337 - 345
  • [3] Risk for initiation of substance use as a function of age of onset of cigarette, alcohol and cannabis use: Findings in a Midwestern female twin cohort
    Agrawal, Arpana
    Grant, Julia D.
    Waldron, Mary
    Duncan, Alexis E.
    Scherrer, Jeffrey F.
    Lynskey, Michael T.
    Madden, Pamela A. F.
    Bucholz, Kathleen K.
    Heath, Andrew C.
    [J]. PREVENTIVE MEDICINE, 2006, 43 (02) : 125 - 128
  • [4] Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP)
    Akbik, Hammam
    Butler, Stephen F.
    Budman, Simon H.
    Fernandez, Katherine
    Katz, Nathaniel P.
    Jamison, Robert N.
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2006, 32 (03) : 287 - 293
  • [5] *AM AC PAIN MED AM, 1996, US OP TREATM CHRON P
  • [6] American Pain Society, 2003, PRINC AN US TREATM A
  • [7] American Pain Society, GUID MAN CANC PAIN A
  • [8] Accuracy in equianalgesic dosing: Conversion dilemmas
    Anderson, R
    Saiers, JH
    Abram, S
    Schlicht, C
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2001, 21 (05) : 397 - 406
  • [9] [Anonymous], ABC NEWS
  • [10] [Anonymous], 2008, NIH PUBLICATION